登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma
ClinicalTrials.gov 上登记的一项淋巴瘤开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06479356,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 6
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(6 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Subjects must have histologically confirmed Large B-cell Lymphoma;
入选标准第 3 条
Subjects had been treated with anthracyclines and rituximab(or other CD20-targeted antibodies) and had relapsed, failed to respond, or progressed after at least two lines of therapy including autologous hematopoietic stem cell transplantation(auto-HSCT);
入选标准第 4 条
Subjects who have previously received CD19 targeted therapy must confirm that lymphoma lesions still express CD19;
入选标准第 9 条
Eastern Cooperative Oncology Group(ECOG) performance status of 0 or 1;
入选标准第 6 条
History of another primary malignancy that has not been in remission for at least 2 years;
排除标准第 2 条
Subjects has HBV,HCV,HIV or syphilis infection at the time of screening;
排除标准第 3 条
Women of childbearing potential must agree to use highly effective methods of contraception for 1 year after the last dose of Relma-cel;
入选标准第 10 条
Males who have partners of childbearing potential must agree to use an effective barrier contraceptive method for 1 year after the last dose of Relma-cel.
入选标准第 11 条
Pregnant or nursing woman;
排除标准第 8 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;影像与可测量病灶。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06479356,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
≥18 years old; Sign on the informed consent; Subjects must have histologically confirmed Large B-cell Lymphoma; Subjects had been treated with anthracyclines and rituximab(or other CD20-targeted antibodies) and had relapsed, failed to respond, or progressed after at least two lines of therapy including autologous hematopoietic stem cell transplantation(auto-HSCT); Subjects have accessible PET-positive lesion and have measurable CT-positive lesion according to Lugano Classification; Eastern Cooperative Oncology Group(ECOG) performance status of 0 or 1; Adequate organ function; Adequate vascular access for leukapheresis procedure; Subjects who have previously received CD19 targeted therapy must confirm that lymphoma lesions still express CD19; Women of childbearing potential must agree to use highly effective methods of contraception for 1 year after the last dose of Relma-cel; Males who have partners of childbearing potential must agree to use an effective barrier contraceptive method for 1 year after the last dose of Relma-cel.排除标准:Exclusion Criteria:
Primary CNS lymphoma; History of another primary malignancy that has not been in remission for at least 2 years; Subjects has HBV,HCV,HIV or syphilis infection at the time of screening; Active deep venous thrombosis(DVT)/Pulmonary embolism(PE),or active DVT/PE requires anti-coagulation within 3 months prior to signing the ICF; Subjects with uncontrolled systemic fungal,bacterial,viral or other infection; Presence of acute or chronic graft-versus-host disease(GVHD); History of any serious cardiovascular disease or presence of clinically relevant CNS pathology; Pregnant or nursing woman; Subjects using of any chemotherapy,corticosteroid,experiment agents,GVHD therapies,radiation,allo-HSCT or any other therapies for lymphoma must go through a specific wash-out period before leukapheresis; Uncontrolled conditions or unwillingness or inability to follow the procedures required in the protocol; Received CAR T-cell or other genetically-modified T-cell therapy previously.
引自 ClinicalTrials.gov, NCT06479356, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06479356,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。